Skip to main content

Articles

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL
Read More
Original Research
Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use
Stakeholder Perspective
Using Statin Therapy to Reduce Atherosclerotic Cardiovascular Disease Risk
Read More
Practice Management
Healthcare Spending: Plenty of Blame to Go Around
Read More
Original Research
Treatment Patterns and Outcomes in Patients with Varicose Veins
Stakeholder Perspective
Important Insights from Real-World Treatment Patterns and Outcomes for Varicose Veins Management
Read More
Perspectives
From Cells to Society
Read More
Practice Management
Effects of Specialty Pharmacy Care on Health Outcomes in Multiple Sclerosis
Stakeholder Perspective
What Makes Specialty Pharmacy Care So Special?
Read More
Page 104 of 244
Results 1031 - 1040 of 2434